The hybridoma technique set the scene for the development of therapeutic antibodies because it enabled the generation of:

1. totally human antibodies from humanized antibodies.
2. chimeric antibodies from mouse antibodies.
3. mouse monoclonal antibodies from a polyclonal population of mouse B cells.
4. humanized antibodies from chimeric antibodies.